Verona Pharma PLC | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
603.80
9,969.80
3,524.40
39,785.00
80,262.00
64,703
Total Accounts Receivable
107.20
922.90
1,851.80
1,067.00
5,006.00
5,600
Other Current Assets
142.40
364.60
196.30
2,959.00
1,810.00
1,362
Total Current Assets
853.40
11,257.30
5,572.50
43,811.00
87,078.00
71,665
Net Property, Plant & Equipment
27.60
21.80
13.20
14.00
16.00
21
Intangible Assets
1,676.30
1,849.70
2,254.80
2,318.00
2,410.00
2,575
Total Assets
2,557.30
13,128.80
7,840.40
46,143.00
89,504.00
74,261
Accounts Payable
329.80
366.60
-
-
-
Income Tax Payable
-
-
14.10
126.00
169.00
Other Current Liabilities
159.60
157.70
1,798.70
10,746.00
8,427.00
Total Current Liabilities
489.30
524.30
1,812.70
10,872.00
8,596.00
Other Liabilities
-
-
593.90
802.00
1,027.00
Total Liabilities
489.30
524.30
2,406.70
11,674.00
9,623.00
Common Equity (Total)
2,068.00
12,604.50
5,433.70
34,469.00
79,881.00
Total Shareholders' Equity
2,068.00
12,604.50
5,433.70
34,469.00
79,881.00
Total Equity
2,068.00
12,604.50
5,433.70
34,469.00
79,881.00
Liabilities & Shareholders' Equity
2,557.30
13,128.80
7,840.40
46,143.00
89,504.00

About Verona Pharma

View Profile
Address
3 More London Riverside
London Greater London SE1 2RE
United Kingdom
Employees -
Website http://veronapharma.com
Updated 07/08/2019
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.